Topics:

Taxoprexin Pivotal Studies Begin in Melanoma and Pancreatic Cancer

Taxoprexin Pivotal Studies Begin in Melanoma and Pancreatic Cancer

KING OF PRUSSIA, Pennsylvania—Protarga, Inc. has received comments from the FDA that allow it to proceed with two separate phase III clinical studies of its new cancer drug Taxoprexin Injection (DHA-pacli-taxel) for the treatment of metastatic melanoma and pancreatic cancer. Taxoprexin is made by linking the fatty acid docosahexaenoic acid (DHA) to paclitaxel, the company said in a news release.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.